The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Abstract Vitamin C (Vit C) is a potent antioxidant with several applications in the cosmetic
and pharmaceutical fields. However, the biggest challenge in the utilization of Vit C is to …

The discovery of effective drugs for the treatment of neurodegenerative disorders (NDs) is a
deadlock. Due to their complex etiology and high heterogeneity, progresses in the …

The blood–brain barrier (BBB) acts as a barrier to prevent the central nervous system (CNS)
from damage by substances that originate from the blood circulation. The BBB limits drug …

The non-specificity of standard anticancer therapies has profound detrimental
consequences in clinical treatment. Therapeutic specificity can be precisely achieved using …

Transmembrane transport of small organic and inorganic molecules is one of the
cornerstones of cellular metabolism. Among transmembrane transporters, solute carrier …

The treatment of central nervous system (CNS) malignancies, including brain cancers, is
limited by a number of obstructions, including the blood-brain barrier (BBB), the …

Introduction Brain diseases including brain tumor, Alzheimer's disease, Parkinson's disease,
etc. are difficult to treat. The blood–brain barrier (BBB) is a major obstacle for drug delivery …

Neurodegenerative diseases (NDs) such as Alzheimer's disease (AD) and Parkinson's
disease (PD) are an accelerating global health problem as life expectancy rises worldwide …

Targeted drug delivery across the blood–brain barrier is an extremely challenging quest in
the fight with fatal brain ailments, with the major hurdles being short circulation time …